Related Experiment Video

Updated: May 23, 2026

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

Use of sirolimus in patients with primary steroid-resistant nephrotic syndrome

Miguel Liern1, Verónica De Reyes, Alicia Fayad

  • 1Hospital de Niños Ricardo Gutiérrez, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.

Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia
|April 18, 2012
PubMed

Insights

Sirolimus shows promise for treating persistent nephrotic syndrome unresponsive to standard therapies. Early intervention with sirolimus may improve outcomes in patients with focal and segmental glomerulosclerosis, potentially slowing kidney disease progression.

Area of Science:

  • Nephrology
  • Pharmacology
  • Pediatric Nephrology

Background:

  • Persistent nephrotic syndrome can lead to kidney failure.
  • Steroid-resistant nephrotic syndrome (SRNS) presents a significant therapeutic challenge.
  • Focal and segmental glomerulosclerosis (FSGS) is a common cause of SRNS.

Purpose of the Study:

  • To evaluate the efficacy of sirolimus in patients with SRNS.
  • To assess the impact of disease duration and histological damage on treatment response.
  • To determine if sirolimus is a viable treatment option for refractory nephrotic syndrome.

Main Methods:

  • Prospective, interventional, time series, cohort study over 20 months.
  • Thirteen pediatric patients (mean age 10 years) with SRNS and FSGS were enrolled.
  • Sirolimus administered at 3.6mg/m2/day for up to 12 months, with proteinuria reduction as the primary efficacy endpoint.

Main Results:

  • Nine out of 13 patients (69%) responded to sirolimus treatment.
  • Response to therapy was influenced by mean progression time and severity of histological renal damage.
  • Total, partial, and no response categories were used to assess proteinuria reduction.

Conclusions:

  • Sirolimus is a potential therapeutic option for steroid-resistant nephrotic syndrome.
  • Earlier initiation of sirolimus treatment may be crucial for better outcomes.
  • Further research is warranted to optimize sirolimus therapy in SRNS and FSGS.

More Related Videos

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...